Glycopyrrolate + Formoterol

Form: Pressurized metered-dose inhaler (pMDI)

Strength: Glycopyrrolate 9 mcg + Formoterol fumarate 4.8 mcg

Reference Brands: Bevespi Aerosphere(US)

Category: Respiratory Disorder

Glycopyrrolate + Formoterol is a long-acting bronchodilator combination used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate, a LAMA, and Formoterol, a LABA, work together to relax airway muscles, improve airflow, and reduce symptoms like breathlessness. Marketed as Bevespi Aerosphere in the United States, this combination is delivered via a pressurized metered-dose inhaler (pMDI) and taken twice daily. It is not intended for acute symptom relief but provides long-term control of COPD symptoms. Bevespi Aerosphere helps enhance lung function, reduce exacerbations, and improve the overall quality of life for patients with moderate to severe COPD.